As Breast Cancer Outcomes Improve, Racial Disparities Linger

Investigators are assessing FORE8394, which received orphan drug designation from the FDA, in primary brain and central nervous system malignancies in the phase 2 FORTE trial.

Minh-Tri Nguyen, MD, spoke with CancerNetwork® about differences between time to treatment, socioeconomic status, and clinical outcomes in rural and urban patients with breast cancer.

Data from the phase 2 INNATE trial indicate that pimivalimab plus JTX-8064 also appears to be well tolerated in patients with platinum-resistant ovarian cancer.

Experts from Emory Winship Cancer Institute discuss how the FDA approval of sacituzumab govitecan will impact the treatment of breast cancer.

Enzalutamide plus leuprolide appears to improve metastases-free survival vs placebo plus leuprolide in patients with non-metastatic hormone-sensitive prostate cancer.

The phase 3 LIMBER-304 trial examining parsaclisib with ruxolitinib vs matched placebo will be discontinued after an interim analysis concluded it would likely miss the primary end point.